Omnicare takes over the specialty wholesaler Megapharm. The cyto-cooperation thus not only secures market share, but also access to new technical service offerings.
Omnicare is the leading pharmaceutical manufacturer of patient-specific infusion solutions. All infusion solutions are manufactured under sterile conditions in state-of-the-art pharmacy laboratories from finished medicinal products approved in Germany.
Megapharm was founded in 1993 and currently has more than 200 pharmacies as customers. In addition to purchasing, services are the second important pillar of the company. Last year, megapharm's turnover alone amounted to 380 million euros. As a result of the merger, the merged Omnicare/megapharm is now a major provider in the market of cyto-specialty wholesalers and compounders with a cumulative turnover of well over half a billion euros per year.
The parties have agreed not to disclose the purchase price.
Alliance Boots initially acquired 90 percent of the shares in October 2008; one year later, the British pharmaceutical retailer took over the company completely. However, the market has changed considerably since then: The large manufacturing companies have long had their own suppliers and approvals; many independent cyto-pharmacists joined forces in 2012 to form Omnicare and have been purchasing together via this route ever since.
ConAlliance advises on corporate transactions, both company sales and acquisitions, in the niche of cyto-specialty wholesalers and compounders.